氨溴索治疗戈谢病相关肝硬化门静脉高压症1例报告
DOI: 10.3969/j.issn.1001-5256.2021.04.037
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:张玮负责资料分析,撰写论文;崔仕元、王珊珊、郑美芳、张鹏参与收集数据,修改论文;高润平负责拟定写作思路,指导撰写文章并最后定稿。
Ambroxol for treatment of liver cirrhosis and portal hypertension in Gaucher disease: A case report
-
-
Key words:
- Gaucher Disease /
- Liver Cirrhosis /
- Ambroxol
-
[1] CARUBBI F, CAPPELLINI MD, FARGION S, et al. Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist[J]. Dig Liver Dis, 2020, 52(4): 368-373. DOI: 10.1016/j.dld.2020.01.004. [2] NASCIMBENI F, CASSINERIO E, DALLA SALDA A, et al. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease[J]. Mol Genet Metab, 2018, 125(1-2): 64-72. DOI: 10.1016/j.ymgme.2018.08.004. [3] DEBNATH CR, DEBNATH MR, NABI N, et al. A case of Gaucher's disease progressing to liver cirrhosis[J]. Mymensingh Med J, 2013, 22(2): 394-396. http://www.ncbi.nlm.nih.gov/pubmed/23715368 [4] ZIMRAN A, ALTARESCU G, ELSTEIN D. Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease[J]. Blood Cells Mol Dis, 2013, 50(2): 134-137. DOI: 10.1016/j.bcmd.2012.09.006. [5] PAWLINSKI L, KRAWCZYK M, FIEMA M, et al. Dual-action ambroxol in treatment of chronic pain in Gaucher disease[J]. Eur J Pain, 2020, 24(5): 992-996. DOI: 10.1002/ejp.1538. [6] HAN TU, SAM R, SIDRANSKY E. Small molecule chaperones for the treatment of gaucher disease and GBA1-associated parkinson disease[J]. Front Cell Dev Biol, 2020, 8: 271. DOI: 10.3389/fcell.2020.00271. [7] NGUYEN Y, STIRNEMANN J, BELMATOUG N. Gaucher disease[J]. Rev Prat, 2020, 70(4): 416-420.